title: Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome.
abstract: BACKGROUND
  Stanniocalcin1 (STC1) is a hormone that regulates cell growth and survival; this study aimed to evaluate the STC1 gene expression in patients with acute leukemia and assess its prognostic significance.
  
  
  METHODS
  Seventy-six patients with acute leukemia were enrolled for determination of mRNA STC1 by real-time quantitative polymerase chain reaction at diagnosis and at day 28.
  
  
  RESULTS
  Median STC1 gene expression was 16.2 and 4.43 in patients with acute myeloid leukemia and 9.67 and 2.37 in patients with acute lymphoblastic leukemia on days 0 and 28, respectively. A cutoff level for STC1 gene expression was established subdividing patients into high- and low-STC1 gene expression groups. Median STC1 gene expression at days 0 and 28 was significantly higher among patients who were nonresponders to therapy than among those who were therapy responders in both groups. Patients achieving complete remission had significantly lower baseline STC1 gene expression than those in relapse. High STC1 gene expression was associated with shorter overall and disease-free survival times.
  
  
  CONCLUSIONS
  STC1 gene expression at diagnosis might be a useful prognostic marker for clinical outcome and monitoring therapeutic response in patients with acute leukemia.
authors.affiliation: Clinical Pathology Department, Ain Shams University, Cairo, Egypt.
authors.forename: H M H
authors.initials: HM
authors.lastname: Abaza
authors.affiliation: Clinical Pathology Department, Ain Shams University, Cairo, Egypt.
authors.forename: M I
authors.initials: MI
authors.lastname: Elmougy
authors.affiliation: Clinical Pathology Department, Ain Shams University, Cairo, Egypt.
authors.forename: H M A
authors.initials: HM
authors.lastname: El Maraghy
authors.affiliation: Clinical Pathology Department, Ain Shams University, Cairo, Egypt.
authors.forename: H M
authors.initials: HM
authors.lastname: Mahmoud
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D002869:Chromosome Aberrations; D005260:Female; D015870:Gene Expression; D006023:Glycoproteins / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D015415:Biomarkers; D006023:Glycoproteins; D012333:RNA, Messenger; C051795:teleocalcin
keywords: Acute leukemia; STC1 gene expression; acute lymphoblastic leukemia; acute myeloid leukemia; clinical outcome